Third Rock Ventures Launches Fulcrum Therapeutics with $55M Series A Investment

Download IconDownload Print IconPrint

Third Rock Ventures Launches Fulcrum Therapeutics with $55M Series A Investment

Firm News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Helping clients launch their businesses and transform their innovative ideas into successful companies.

Third Rock Ventures, LLC announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will discover and develop small molecules that modulate the on/off control mechanisms that regulate genes.

Fulcrum was established with $55 million in Series A financing to further develop a cross-disciplinary product engine to identify and modulate gene regulatory targets core to disease. Through its product engine, Fulcrum will develop a robust pipeline across therapeutic areas, spearheaded by two initial programs in genetic diseases.

The WilmerHale team on the deal was led by Partner Lia Der Marderosian, Senior Associate Stephanie Singer and Associate Byron Crowe.

Read the Fulcrum Therapeutics press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel